All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Dr Machaalani on the Interaction Between c-Met and AXL in RCC

August 9th 2024

Marc Machaalani, MD, discusses the rationale for examining AXL and its interaction with c-Met in renal cell carcinoma.

Research Across 5 Sarcoma Stem Cell Subtypes Identifies EZH2 as a Potential Therapeutic Target

August 9th 2024

R. Lor Randall, MD, FACS, details findings from a genetic and epigenetic study showing 5 sarcoma subtypes had EZH2 activity and a shared epigenetic profile.

Dr Grunwald on a Real-World Study of Risk Factors For Disease Progression in PV

August 9th 2024

Michael R. Grunwald, MD, discusses findings from a real-world study of risk factors related to disease progression in polycythemia vera.

Orelabrutinib Plus Lenalidomide and Rituximab Demonstrates Efficacy in Frontline MCL

August 9th 2024

Orelabrutinib in combination with lenalidomide and rituximab was safe and active in treatment-naive mantle cell lymphoma.

CIRT Plus Durvalumab/Tremelimumab Is Safe in Advanced HCC With Macrovascular Invasion

August 8th 2024

CIRT plus durvalumab and tremelimumab was safe in patients with advanced hepatocellular carcinoma with macrovascular invasion.

Olomorasib Plus Pembrolizumab Generates Antitumor Activity in KRAS G12C+ NSCLC

August 8th 2024

Olomorasib plus pembrolizumab demonstrated responses in first-line metastatic KRAS G12C–mutant non–small cell lung cancer.

Pacritinib Demonstrates Safety in Solid Tumors Harboring 1q21.3 Amplifications

August 8th 2024

Pacritinib was tolerable with a reasonable safety profile in patients with solid tumors harboring 1q21.3 copy number amplifications.

Colorado School of Public Health Launches Innovative Program to Support Working Cancer Patients

August 8th 2024

The Colorado School of Public Health announces the launch of WeCanWork, a program to provide support to cancer patients as they balance work and treatment.

Isatuximab Plus VRd Improves PFS in Transplant-Eligible, Newly Diagnosed Myeloma

August 8th 2024

Isatuximab plus VRd induction improved progression-free survival in transplant-eligible, newly diagnosed multiple myeloma.

Merck Discontinues KeyVibe-008 Trial of Vibostolimab/Pembrolizumab Plus Chemo in ES-SCLC

August 8th 2024

The KeyVibe-008 trial evaluating vibostolimab, pembrolizumab, and chemotherapy in extensive-stage small cell lung cancer has been discontinued.

Precision Cancer Medicine: The Past, Present, and Future

August 8th 2024

Treatment After Progression on CDK4/6 Inhibitors Requires Careful Consideration in HR+/HER2– mBC

August 8th 2024

Sarah Sammons, MD, describes how she treats patients with HR-positive, HER2-negative metastatic breast cancer who progressed on prior CDK4/6 inhibitors.

FDA Approves Denileukin Diftitox for R/R Cutaneous T-Cell Lymphoma

August 8th 2024

The FDA has approved denileukin diftitox-cxdl for relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

Leveraging ADCs in Lung Cancer: Snapshot of Existing Challenges and Opportunities

August 7th 2024

Kashul Parikh, MBBS, discusses research efforts dedicated to leveraging antibody-drug conjugates with varying targets in lung cancer.

Real-World Study Reveals Reasons for Pancreatic Cancer Non-Treatment

August 7th 2024

Tilak Sundaresan, MD, and Nicole S. Evans, MD, discuss common reasons for nontreatment among patients with pancreatic cancer.

Paramountcy of Molecular Testing Is Increasing in Early-Stage NSCLC

August 7th 2024

Fred R. Hirsch, MD, PhD, discusses the role of molecular testing in non–small cell lung cancer.

Novel Studies Seek to Optimize HER2+ Breast Cancer Management

August 7th 2024

Sara M. Tolaney, MD, MPH, discusses the use of ADCs in HER2-positive breast cancer and ongoing research in this patient population.

Guardant Reveal Test Is Effective in Predicting Recurrence in Stage II and Higher CRC

August 7th 2024

The Guardant Reveal test was accurate in predicting disease recurrence in stage II or higher colorectal cancer.

Serial Clinical Response Evaluation Aids in Residual Disease Detection in ESCC

August 7th 2024

Bite-on-bite biopsies and endoscopic ultrasonography with fine needle aspiration were accurate in detecting MRD after neoadjuvant chemoradiotherapy in ESCC.

Dana-Farber's Edward Chouchani selected as a Howard Hughes Medical Institute Investigator

August 7th 2024

Edward Chouchani, PhD, of Dana-Farber Cancer Institute, has been named a Howard Hughes Medical Institute Investigator.